Relmada Therapeutics Inc (RLMD)

Jul 10, 2025

Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan

Jul 10, 2025

Jul 09, 2025

Head-To-Head Contrast: Tempest Therapeutics (NASDAQ:TPST) vs. Relmada Therapeutics (NASDAQ:RLMD) - Defense World

Jul 09, 2025

Jul 08, 2025

Relmada Therapeutics (NASDAQ:RLMD) Shares Down 3.1% – What’s Next? - Defense World

Jul 08, 2025

Jun 17, 2025

Relmada Therapeutics (RLMD) Appoints New Chief Medical Officer | - GuruFocus

Jun 17, 2025

Jun 17, 2025

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD a - GuruFocus

Jun 17, 2025

Jun 17, 2025

Relmada Therapeutics appoints Raj Pruthi as CMO, Urology - TipRanks

Jun 17, 2025

Jun 17, 2025

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology | RLMD Stock News - GuruFocus

Jun 17, 2025

Jun 17, 2025

Top Bladder Cancer Expert Joins Relmada as CMO: Phase 3 Trial Launch Set for 2026 - Stock Titan

Jun 17, 2025

Jun 17, 2025

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology - The Manila Times

Jun 17, 2025

Jun 14, 2025

Two Sigma Investments LP Sells 63,736 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World

Jun 14, 2025

Jun 09, 2025

Two Sigma Advisers LP Reduces Holdings in Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World

Jun 09, 2025

May 27, 2025

Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks

May 27, 2025

May 24, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World

May 24, 2025

May 24, 2025

Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World

May 24, 2025

May 20, 2025

RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView

May 20, 2025

May 16, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail

May 16, 2025

May 15, 2025

Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks

May 15, 2025

May 13, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

May 13, 2025

Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com

May 13, 2025

May 13, 2025

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance

May 13, 2025

May 13, 2025

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus

May 13, 2025

May 13, 2025

Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 13, 2025

May 12, 2025

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 12, 2025

May 10, 2025

Relmada Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus

May 10, 2025

May 10, 2025

Relmada Therapeutics (RLMD) Expected to Announce Earnings on Monday - Defense World

May 10, 2025

May 08, 2025

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - The Manila Times

May 08, 2025

May 08, 2025

Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq

May 08, 2025

May 08, 2025

Renaissance Technologies LLC Buys 138,625 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World

May 08, 2025

May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025

May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025

Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025

Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025

Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025

Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025

Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025

Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News

Apr 28, 2025

Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025

Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025

Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025

Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025

Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025

Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025

Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025